search
Back to results

Effects of Pramlintide on Endogenous Production of Very-low-density-lipoprotein (VLDL)-Triglyceride and Glucose in the Post Prandial State in T2DM

Primary Purpose

Type 2 Diabetes

Status
Withdrawn
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Pramlintide acetate
Placebo
Sponsored by
University of Maryland, Baltimore
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type 2 Diabetes focused on measuring triglycerides, endogenous, glucose, production

Eligibility Criteria

20 Years - 60 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Type 2 DM study participants will be C-Peptide positive (levels > 0.3 nmol/L)
  • Receiving insulin, metformin and/or sulfonylurea/glitinide.
  • Maintained on stable anti-hypertensive medication.
  • BMI < 52 kg/m2.
  • T2DM for at least 3 months with HBA1C under 10%.

Exclusion Criteria:

  • Receiving TZDs, exenatide, sitagliptin or pramlintide therapy.
  • Receiving medications known to impair gastric emptying, intestinal motility, glucagon release or corticosteroids.
  • Triglyceride levels > 400 mg/dl.
  • BMI > 52 kg/m2.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Placebo Comparator

    Experimental

    Arm Label

    2

    1

    Arm Description

    Type 2 diabetes patients will receive placebo with 3 meals in experimental period.

    Type 2 Diabetes patient will receive Pramlintide with 3 meals in experimental period.

    Outcomes

    Primary Outcome Measures

    Endogenous glucose production

    Secondary Outcome Measures

    Endogenous VLDL-Triglyceride production

    Full Information

    First Posted
    August 6, 2008
    Last Updated
    July 18, 2021
    Sponsor
    University of Maryland, Baltimore
    Collaborators
    Amylin Pharmaceuticals, LLC.
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT00732147
    Brief Title
    Effects of Pramlintide on Endogenous Production of Very-low-density-lipoprotein (VLDL)-Triglyceride and Glucose in the Post Prandial State in T2DM
    Official Title
    Effects of Pramlintide on Endogenous Production of VLDL-Triglyceride and Glucose in the Post Prandial State in Type 2 Diabetes Mellitus
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    July 2021
    Overall Recruitment Status
    Withdrawn
    Why Stopped
    Sponsor could not fund.
    Study Start Date
    April 2009 (undefined)
    Primary Completion Date
    April 2011 (Actual)
    Study Completion Date
    April 2011 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    University of Maryland, Baltimore
    Collaborators
    Amylin Pharmaceuticals, LLC.

    4. Oversight

    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    Diabetes affects almost 21 million people in the United States. In this study we will test a drug called Pramlintide(Symlin), and see how it works to lower blood sugar and fat levels after a meal. Lowering high sugar levels and fat levels after a meal is very important in the prevention of the problems that persons with type 2 diabetes often encounter. Hypothesis is that Pramlintide will lower blood sugar and fat levels after a meal.
    Detailed Description
    A well recognized and troublesome feature of diabetes management is the exacerbated post prandial glucose elevations following a typical high fat meal. To date the mechanisms driving this increased post prandial glycemia are unclear. Pramlintide is believed to affect intermediary metabolism as well as nutrient absorption. The relative contributions from altered absorption and metabolism to the observed post prandial reductions in plasma glucose and TG concentrations remain uncertain, however. Combinations of radioactive and stable isotope labeling techniques are able to quantify the relevant fluxes of glucose and lipids in vivo in humans and are therefore able to provide quantitative answers to these questions. Aims: To determine the effects of Pramlintide on reducing endogenous production of very-low-density-lipoprotein (VLDL)-triglycerides(TG) following a high fat breakfast, lunch and dinner in patients with type 2 diabetes mellitus (T2DM). A triple isotope approach will be used to determine rate of appearance of (VLDL)-triglycerides following breakfast, lunch and dinner. To compare the relative roles of slowed glucose absorption and reduced endogenous glucose production (glucagonstatic mechanism) in the glucose-lowering effects of Pramlintide in the post prandial state in patients with T2DM.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Type 2 Diabetes
    Keywords
    triglycerides, endogenous, glucose, production

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Not Applicable
    Interventional Study Model
    Factorial Assignment
    Masking
    Participant
    Allocation
    Randomized
    Enrollment
    0 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    2
    Arm Type
    Placebo Comparator
    Arm Description
    Type 2 diabetes patients will receive placebo with 3 meals in experimental period.
    Arm Title
    1
    Arm Type
    Experimental
    Arm Description
    Type 2 Diabetes patient will receive Pramlintide with 3 meals in experimental period.
    Intervention Type
    Drug
    Intervention Name(s)
    Pramlintide acetate
    Other Intervention Name(s)
    Symlin
    Intervention Description
    120 micrograms given subcutaneously before each meal X 3.
    Intervention Type
    Drug
    Intervention Name(s)
    Placebo
    Intervention Description
    120 micrograms given subcutaneously before each meal x 3.
    Primary Outcome Measure Information:
    Title
    Endogenous glucose production
    Time Frame
    18 hours
    Secondary Outcome Measure Information:
    Title
    Endogenous VLDL-Triglyceride production
    Time Frame
    18 hours

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    20 Years
    Maximum Age & Unit of Time
    60 Years
    Accepts Healthy Volunteers
    Accepts Healthy Volunteers
    Eligibility Criteria
    Inclusion Criteria: Type 2 DM study participants will be C-Peptide positive (levels > 0.3 nmol/L) Receiving insulin, metformin and/or sulfonylurea/glitinide. Maintained on stable anti-hypertensive medication. BMI < 52 kg/m2. T2DM for at least 3 months with HBA1C under 10%. Exclusion Criteria: Receiving TZDs, exenatide, sitagliptin or pramlintide therapy. Receiving medications known to impair gastric emptying, intestinal motility, glucagon release or corticosteroids. Triglyceride levels > 400 mg/dl. BMI > 52 kg/m2.
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Stephen N. Davis, MD
    Organizational Affiliation
    Vanderbilt University
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Learn more about this trial

    Effects of Pramlintide on Endogenous Production of Very-low-density-lipoprotein (VLDL)-Triglyceride and Glucose in the Post Prandial State in T2DM

    We'll reach out to this number within 24 hrs